Search alternatives:
tested decrease » teer decrease (Expand Search), step decrease (Expand Search), reported decrease (Expand Search)
marked decrease » marked increase (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
were tested » were treated (Expand Search), were detected (Expand Search), three tested (Expand Search)
tested decrease » teer decrease (Expand Search), step decrease (Expand Search), reported decrease (Expand Search)
marked decrease » marked increase (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
were tested » were treated (Expand Search), were detected (Expand Search), three tested (Expand Search)
-
1
-
2
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
Overview of the six original ACTIV-3/TICO trials.
Published 2025“…Anti-nucleocapsid response was similar at day 28 (mean difference in S/C ratio: 0.02 [95%CI: −0.11, 0.15], p = 0.75) and day 90 (mean difference in S/C ratio: 0.08 [95% CI: −0.05, 0.21], p = 0.22). Similar patterns were observed in all trials.</p><p>Conclusions</p><p>In patients hospitalized with COVID-19, treatment with nMAbs did not decrease long-term anti-nucleocapsid response compared to placebo, suggesting neutralizing therapies do not suppress the endogenous humoral immune response in this population.…”
-
16
-
17
-
18
-
19
-
20